Polymorphisms in the hMSH2 gene and the risk of primary lung cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 4, 2006, Pages 762-768

  Chi, Young Jung ^a   Jin, Eun Choi ^a   Jung, Min Park ^a   Myung, Hwa Chae ^a   Kang, Hyo Gyoung ^a   Kyung, Mee Kim ^a   Su, Jeong Lee ^a   Won, Kee Lee ^a   Kam, Sin ^a   Seung, Ick Cha ^a   Chang, Ho Kim ^a   Sung, Beom Han ^b   Tae, Hoon Jung ^a   Su, Han Jeon ^c   Jae, Yong Park ^a,c  

^a Kyungpook National University   (South Korea)

^b Keimyung University   (South Korea)

^c Kyungpook National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MSH2;

ADENOCARCINOMA; ADULT; ALLELE; ARTICLE; BAYES THEOREM; CANCER RISK; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HAPLOTYPE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SMOKING;

ADENOCARCINOMA; CASE-CONTROL STUDIES; DNA DAMAGE; FEMALE; HAPLOTYPES; HUMANS; KOREA; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; ODDS RATIO; POLYMORPHISM, GENETIC;

EID: 33646252952     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0834     Document Type: Article

References (56)

1. Shields PG, Harris CC. Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J Clin Oncol 2000;18:2309-15.
2. Mohrenweiser HW, Jones IM. Variation in DNA repair is a factor in cancer susceptibility: a paradigm for the promise and perils of individuals and population risk estimation? Mutat Res 1998;400:15-24.
3. Wood EC, Mitchell M, Sgouros J, et al. Human DNA repair genes. Science 2001;291:1284-8.
4. Bernstein C, Bernstein H, Payne CM, et al. DNA repair/pro-apoptotic dual role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res 2002;511:145-78.
5. Cheng L, Eicher SA, Guo Z, et al. Reduced DNA repair capacity in head and neck cancer patients. Cancer Epidemiol Biomarkers Prev 1998;7:465-8.
6. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:1513-30.
7. Park JY, Lee SY, Jeon HS, et al. Polymorphisms of the DNA repair gene XRCC1 and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 2002;11:23-7.
8. Park JY, Lee SY, Jeon H-S, et al. Lys751Gln polymorphism of the DNA repair gene XPD and risk of primary lung cancer. Lung Cancer 2002;36:15-6.
9. Park JY, Park SH, Choi JE, et al. Polymorphism of the DNA repair gene XPA and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 2002;11:993-7.
10. Kolodner RD. Mismatch repair: mechanisms and relationship to cancer susceptibility. Trends Biochem Sci 1995;20:397-401.
11. Bellacosa A. Functional interactions and signaling properties of mammalian DNA mismatch repair proteins. Cell Death Differ 2004;25:1821-7.
12. Duval A, Hamelin R. Mutations at coding repeat sequences in mismatch repair deficient human cancers: toward a new concept of target genes for instability. Cancer Res 2002;62:2447-54.
13. Simpkins SB, Bocker T, Swisher EM, et al. MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic cancers. Hum Mutat Genet 1999;8:661-6.
14. Boland CR, Thibodeau SN, Hamilton SR, et al. A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-57.
15. Park JY, Jeon H-S, Park SH, et al. Microsatellite alteration in histologically normal lung tissue of patients with non-small cell lung cancer. Lung Cancer 2000;30:83-9.
16. Wu J, Gu L, Wang H, et al. Mismatch repair processing of carcinogen-DNA adducts triggers apoptosis. Mol Cell Biol 1999;19:8292-301.
17. Hickman MJ, Samson LD. Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc Natl Acad Sci 1999;96:10764-9.
18. Mellon I, Rajpal DK, Koi M, et al. Transription-coupled deficiency and mutations in mismatch repair genes. Science 1996;272:557-60.
19. Bertrand P, Tishkoff DX, Filosi N, et al. Physical interaction between components of DNA mismatch repair and nucleotide excision repair. Proc Natl Acad Sci 1998;95:14278-83.
20. Borresen AL, Lothe RA, Meling GI, et al. Somatic mutations in the hMSH2 gene in microsatellite unstable colorectal carcinomas. Hum Mol Genet 1995;4:2065-72.
21. Bubb VJ, Curtis LJ, Cunningham C, et al. Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. Oncogene 1996;12:2641-9.
22. Wehner M, Buschhausen L, Lamberti C, et al. Hereditary nonpolyposis colorectal cancer (HNPCC): eight germline mutations in hMSH2 or hMLH1 genes. Hum Mutat 1997;10:241-4.
23. Herfarth KKF, Kodner IJ, Whelan AJ, et al. Mutations in MLH1 are more frequent than in MSH2 in sporadic colorectal cancers with microsatellite instability. Genes Chromosomes Cancer 1997;18:42-9.
24. Viel A, Genuardi M, Capozzi E, et al. Characterization of MSH2 and MLH1 mutations in Italian families with hereditary nonpolyposis colorectal cancer. Genes Chromosomes Cancer 1997;18:8-18.
25. Wahlberg SS, Nystrom-Lahti M, Kane MF, et al. Low frequency of hMSH2 mutations in Swedish HNPCC families. Int J Cancer 1997;74:134-7.
26. Iwahashi Y, Ito E, Yanagisawa Y, et al. Promoter analysis of the human mismatch repair gene hMSH2. Gene 1998;213:141-7.
27. Palicio M, Blanco I, Tortola S, et al. Intron splice acceptor site polymorphism in the hMSH2 gene in sporadic and familial colorectal cancer. Br J Cancer 2000;82:535-7.
28. Paz-y-Mino C, Perez JC, Fiallo BF, et al. A polymorphism in the hMSH2 gene (gIVS12-6T>C) associated with non-Hodgkin lymphomas. Cancer Genet Cytogenet 2002;133:29-33.
29. Caldes T, Godino J, de la Hoya M, et al. Prevalence of germline mutations in MLH1 and MSH2 in hereditary nonpolyposis colorectal cancer families from Spain. Int J Cancer 2002;98:774-9.
30. Kurzawski G, Safranow K, Suchy J, et al. Mutation analysis of MLH1 and MSH2 genes performed by denaturing high-performance liquid chromatography. J Biochem Biophys Methods 2002;51:89-100.
31. Isidro G, Matos S, Goncalves V, et al. Novel MLH1 mutations and a novel MSH2 polymorphism identified by SSCP and DHPLC in Portuguese HNPCC families. Hum Mutat 2003;22:419-20.
32. Worrillow LJ, Travis LB, Smith AG, et al. An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin Cancer Res 2003;9:3012-20.
33. Hishida A, Matsuo K, Hamajima N, et al. Polymorphism in the hMSH2 gene (gIVS12-6T→C) and risk of non-Hodgkin lymphoma in a Japanese population. Cancer Genet Cytogenet 2003;147:71-4.
34. Lee SJ, Jeon H-S, Jang JS, et al. DNMT3B polymorphisms and risk of primary lung cancer. Carcinogenesis 2005;26:403-9.
35. Lee SJ, Lee SY, Jeon H-S, et al. Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 2005;14:571-5.
36. Lewontin RC. On measures of gametic disequilibrium. Genetics 1998;120:849-52.
37. Stephens M, Smith MJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89.
38. Risch NJ. Searching for genetic determinants in the new millennium. Nature 2000;405:847-56.
39. Rebbeck TR, Ambrosone CB, Bell DA, et al. SNPs, haplotypes, and cancer: applications in molecular epidemiology. Cancer Epidemiol Biomarkers Prev 2004;13:681-7.
40. Deutsch-Wenzel R, Brune H, Grimmer G, et al. Experimental studies in rat lungs on the carcinogenicity and dose-response relationships of eight frequently occurring environmental polyaromatic hydrocarbons. J Natl Cancer Inst 1983;71:539-44.
41. Hoffman D, Rivenson A, Murphy SE, et al. Cigarette smoking and adenocarcinoma of the lung: the relevance of nicotine-derived nitrosamines. J Smoking Relat Disord 1993;4:165-90.
42. Smith CJ, Livingston SO, Doolittle DJ. An international literature survey of "IARC group I carcinogens" reported mainstream cigarette smoke. Food Chem Toxicol 1997;35:1107-30.
43. Gu J, Spitz MR, Yang F, et al. Ethnic differences in poly(ADP-ribose) polymerase pseudogene genotype distribution and association with lung cancer risk. Carcinogenesis 1999;20:1465-9.
44. Xinarianos G, Liloglou T, Prime W, et al. hMLH1 and hMSH2 expression correlates with allelic imbalance on chromosome 3p in non-small cell lung cancer. Cancer Res 2000;60:4216-21.
45. Wang YC, Lu YP, Tseng RC, et al. Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. J Clin Invest 2003;111:887-95.
46. Hsu HS, Wen CK, Tang YA, et al. Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer. Clin Cancer Res 2005;11:5410-6.
47. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005;23:857-65.
48. Gazdar AF, Shigematsu H, Herz J, et al. Mutations and addiction to EGFR: the Achilles "heal" of lung cancers? Trends Mol Med 2004;10:481-6.
49. Judson R, Stephens JC, Windemuth A. The predictive power of haplotypes in clinical response. Pharmacogenomics 2000;1:15-26.
50. Judson R, Stephens JC. Notes from the SNP vs. haplotype front. Pharmacogenomics 2001;2:7-10.
51. Leng S, Cheng J, Zhang L, et al. The association of XRCC1 haplotypes and chromosomal damage levels in peripheral blood lymphocytes among coke-oven workers. Cancer Epidemiol Biomarkers Prev 2005;14:1295-301.
52. Brentnall TA, Rubin CE, Crispin DA, et al. A germline substitution in the human MSH2 gene is associated with high-grade dysplasia and cancer in ulcerative colitis. Gastroenterology 1995;109:151-5.
53. Goessl C, Plaschke J, Pistorius S, et al. An intronic germline transition in the HPNCC gene hMSH2 is associated with sporadic colorectal cancer. Eur J Cancer 1997;30A:1550-2.
54. Xia L, Shen W, Ritacca F, et al. A truncated hMSH2 transcript occurs as a common variant in the population: implication for genetic diagnosis. Cancer Res 1996;56:2289-92.
55. Mori Y, Shiwaku H, Fukushige S, et al. Alternative splicing of hMSH2 in normal human tissues. Hum Genet 1997;99:590-5.
56. Genuardi M, Viel A, Bonora D, et al. Characterization of MLH1 and MSH2 alternative splicing and its relevance to molecular testing of colorectal cancer. Hum Genet 1998;102:15-20.